Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05407311 · ClinicalTrials.gov registry record · Phase 2
64Cu-SAR-BBN for Identification of Participants With Recurrence of Prostate Cancer (SABRE)
A Phase 2 study, sponsored by Clarity Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 53
- Enrollment target
NCT05407311 is a Phase 2 study that has completed, run by Clarity Pharmaceuticals. The registered enrollment target is 53 participants.
The verdict
NCT05407311, a Phase 2 study, has completed, sponsored by Clarity Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 53 participants
- Enrollment target
Study Summary
The aim of this study is to determine the safety and efficacy of 64Cu-SAR-BBN and determine the ability of 64Cu-SAR-BBN Positron emission tomography (PET)/computed tomography (CT) to correctly detect the recurrence of prostate cancer in participants with prostate-specific membrane antigen (PSMA)-negative biochemical recurrence of prostate cancer following definitive therapy.
Interventions
- DRUG 64Cu-SAR-BBN
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2022-09-19 |
| Est. Completion | 2024-05-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05407311
The ClinicalTrials.gov registry entry for NCT05407311 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Clarity Pharmaceuticals, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 64Cu-SAR-BBN is the first listed.
NCT05407311 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05407311 about?
NCT05407311 is a clinical study titled "64Cu-SAR-BBN for Identification of Participants With Recurrence of Prostate Cancer (SABRE)". The aim of this study is to determine the safety and efficacy of 64Cu-SAR-BBN and determine the ability of 64Cu-SAR-BBN Positron emission tomography (PET)/computed tomography (CT) to correctly detect the recurrence of prostate cancer in participants with prostate-specific membrane antigen (PSMA)-neg...
What is the current status of trial NCT05407311?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 53 participants. The study started on 2022-09-19. Estimated completion is 2024-05-13.
What interventions are being tested in trial NCT05407311?
The interventions under investigation include: 64Cu-SAR-BBN (DRUG).
Who is sponsoring clinical trial NCT05407311?
This trial is sponsored by Clarity Pharmaceuticals, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.